Hardy Gil, Hardy Ines, McElroy Bruce
Pharmaceutical Nutrition Research Group, Witney, Oxford and Pharmacy Department, Royal Shrewsbury Hospital, UK.
Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):671-7. doi: 10.1097/00075197-200211000-00010.
To review pharmaceutical aspects of selected amino acids, antioxidants and related nutraceuticals, deemed to be important for clinical nutrition.
New clinical applications of nutraceuticals are increasingly being reported, but there are fundamental differences between formulation, production and the evidence supporting clinical use. Nutraceuticals generally fall within the novel foods and ingredients regulations but their purity, dosage requirements and clinical consequences exceed those of most 'healthfoods'. Replacement of one nutrient or antioxidant is unlikely to correct the cascade of interconnected metabolic abnormalities associated with many diseases. However, it is difficult to ascertain whether the reported benefits of complex mixtures, with little published stability data, are due to one or more individual substrates or some in-vitro interaction between them. Many clinical studies have suffered from inconsistencies of dose, formulation discrepancies and unproven outcome. These contradictory results weaken any firm evidence base to substantiate their effectiveness.
Nutraceuticals are destined to play an important role in future therapeutic developments but their success will be governed by control of purity, safety and efficacy without inhibiting innovation. The straightforward application of pharmaceutical standards, especially across national borders, is likely to be a difficult challenge and could effectively paralyse the industry. Nevertheless more standardized formulations, dosage forms and production controls are called for. A place for nutraceuticals in clinical practice is emerging, but important pharmaceutical and clinical issues need to be addressed by further research.
综述特定氨基酸、抗氧化剂及相关营养保健品的药学方面内容,这些被认为对临床营养很重要。
营养保健品的新临床应用报道日益增多,但在制剂、生产以及支持临床使用的证据方面存在根本差异。营养保健品通常属于新型食品和成分法规范畴,但其纯度、剂量要求和临床后果超过大多数“健康食品”。替换一种营养素或抗氧化剂不太可能纠正与许多疾病相关的一系列相互关联的代谢异常。然而,很难确定报道的复杂混合物的益处(几乎没有公开的稳定性数据)是由于一种或多种单独的底物,还是它们之间的某种体外相互作用。许多临床研究存在剂量不一致、制剂差异和未经验证的结果等问题。这些相互矛盾的结果削弱了任何确凿的证据基础来证实其有效性。
营养保健品注定在未来治疗发展中发挥重要作用,但其成功将取决于在不抑制创新的情况下对纯度、安全性和有效性的控制。直接应用药学标准,尤其是跨国界应用,可能是一项艰巨挑战,甚至可能使该行业陷入瘫痪。尽管如此,仍需要更标准化的制剂、剂型和生产控制。营养保健品在临床实践中的地位正在显现,但重要的药学和临床问题需要通过进一步研究来解决。